CJ Bioscience, Inc. (KOSDAQ: 311690)

Market Cap	123.73B
Revenue (ttm)	3.97B
Net Income (ttm)	-21.62B
Shares Out	13.07M
EPS (ttm)	-2,370.64
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,139
Average Volume	34,413
Open	9,670.00
Previous Close	9,740.00
Day's Range	9,660.00 - 9,760.00
52-Week Range	8,250.00 - 18,800.00
Beta	0.95
RSI	40.55
Earnings Date	Mar 20, 2025

About CJ Bioscience

CJ Bioscience, Inc. provides microbiome solutions to address unmet medical needs in South Korea and internationally. The company’s platform is Ez-Mx, a bioinformatics-based platform for microbiome data analysis. Its product pipeline includes CJRB-101 that is phase I clinical trial for solid tumors; CJRB-201, CJRB-202, and CJRB-203 for inflammatory bowel diseases; CJRB-302 for Parkinson’s diseases; CJRB-401 and CJRB-402 for asthma. The company also provides next-generation sequencing analysis services; EzBioCloud, a database and bioinformatics a...

• Industry: Computer Programming, Data Processing, And Other Computer Related Services
• Founded: 2009
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 311690

Financial Performance

In 2023, CJ Bioscience's revenue was 5.58 billion, an increase of 36.82% compared to the previous year's 4.07 billion. Losses were -22.91 billion, -34.37% less than in 2022.